With the clinical validation of tools such as the AUC:EC50 for predicting antimicrobial PD in individuals using markers such as CRP, future work must now explore the role of using newer infection-related biomarkers, such as procalcitonin and CD64 for improving the accuracy of these tools. This evidence concerns the gene CRP and infection.